History

2013
Launch of Multifort Cardio mineral supplement
for protection and strength of cardiac muscle.
Multifort
Cardio
The company is one of the leaders on clinical trials market among Russian companies ***
*** According to Synergy Research Group data for 1st quarter of 2009
Anaferon is awarded Brand #1 in Russia 2013 prize in antiviral medicines
2012
Launch of Brizantin
for alleviating
symptoms of giving -up smoking
Brizantin

10 years of confidence in Anaferon kids

Anaferon kids is the most
prescribed medicine
for children*.

* According to Comcon-Pharma data for 2012

GMP certificates

Materia Medica obtained certificates from State administration of Ukraine on Medicinal Products (SAUMP) and Slovakia State Institute for Drug control (SIDC)

Impaza’s 10th anniversary

Impaza is the most known brand in its category on Russian market **

** According to Comcon-Pharma data for 2012

2011
The company introduced Dietressa,
medicine for weight loss.
Dietressa

Production expansion and launch of vitamin-mineral supplements

Multifort and Multifort kids (dietary supplement)

The company established representative office in South-East Asia
Launch of innovative Ergoferon, new antiviral medicine with complex activity mechanism for treatment of flu and acute viral respiratory diseases.
Ergoferon
2010
Impaza got patent in US and registration in EU
The company got GMP certificates
2009
Representative office started working in Kazakhstan
Anaferon and Afala received US patents.
2008

Launch
of Tenoten kids

Tenoten kids is the only sedative medicine developed especially for children in accordance with children constitution features.

Tenoten
kids

Changes in registration status
of Anaferon and Anaferon kids

The medical community officially recognized that Anaferon and Anaferon kids are medicinal products and no more homeopathic ones.

Materia Medica opened representative offices in Uzbekistan and Belarus
2007

The manufactory in Tchelyabinsk opened new workshops and expanded production

New hi-tech equipement from Italy and Germany enables to unify full production cycle of solid dosage forms.

2006
The company became laureate of Russian Federation Government Prize
for development of new class of medicines.
Launch of Afala
for treatment of prostate adenoma and chronic prostatitis.
Afala
2005
Launch of Tenoten
for alleviating symptoms of anxiety and stress.
Tenoten
2003
Launch of Artrofoon
for treatment of joint diseases.
Artrofoon
2002
Launch of Impaza for treatment of erectile dysfunction.
Impaza

The company introduced
Anaferon kids and Anaferon

Safe treatment and effective prophylaxis of flu and acute viral respiratory infections. Anaferon kids is specially developed for kids’ age.

Anaferon
Anaferon
kids
2000
Launch of Proproten-100, first medicine of the new class for treatment
of alcoholic dependence.
Proproten-
100
1999

Discovery of phenomenons of overdilute solutions

The company started intensive multi-centre clinical trials and developments of the new class of medicines based on ultra-low doses of antibodies to endogenous regulators.

Materia Medica opens its representative office in Ukraine.
1992

1999

At the end of nineties the company’s portfolio included 10 homeopathic medicines of different pharmacological groups

Owing to combination of high safety profile and efficacy, homeopathic medicines quickly gained doctors’ and patients’ confidence.

First in Russia
mass production of
homeopathic medicines

Established in 1992 Materia Medica Holding launched first in Russia mass production of homeopathic medicines and made it available for a wide range of customers.